SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announces positive Phase III SANOVO trial results showing…

HUTCHMED (China) Ltd · 6-K filed Aug 31, 2026 at 06:03 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 31, 2026 at 06:03 ET

HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) significantly improves progression-free survival vs TAGRISSO alone in first-line MET-overexpressing EGFR-mutated NSCLC in China. The combination also demonstrated encouraging overall survival benefit. This expands the clinical value of the all-oral combination into the first-line setting, building on prior SACHI and SAFFRON trials. The data will be submitted to regulatory authorities for label expansion in China.

  • SANOVO Phase III met primary endpoint: statistically significant and clinically meaningful PFS improvement vs TAGRISSO alone in both high MET and ITT populations
  • Encouraging OS benefit observed as secondary endpoint; trial continues follow-up
  • Safety profile consistent with known profiles of each medicine; no new safety findings
  • 326 treatment-naïve patients randomized 1:1 to ORPATHYS+TAGRISSO vs TAGRISSO+placebo

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access